Julie Gerberding

Julie Louise Gerberding (born August 22, 1955) is an American infectious disease expert who was the first woman to serve as the director of the U.S. Centers for Disease Control and Prevention (CDC).

As of May 2022, she is the CEO of the Foundation for the National Institutes of Health (FNIH).

Gerberding grew up in Estelline, South Dakota, attended Brookings High School, and earned undergraduate and graduate degrees from Case Western Reserve University.

She was the chief medical resident at the University of California, San Francisco where she treated hospitalized AIDS patients in the first years of the epidemic.

Gerberding grew up in Estelline, South Dakota and attended Brookings High School and Case Western Reserve University, where she earned an undergraduate degree in biology in 1977 and an M.D. in 1981.

She completed her internship and was the chief medical resident at the University of California San Francisco, where she also completed a fellowship in clinical pharmacology and infectious diseases.

Gerberding was an assistant professor at UCSF from 1988-1995 and the director of the Epidemiology and Prevention Interventions Center at San Francisco General Hospital from 1990-1998.

She also earned an M.P.H. degree from the University of California Berkeley in 1990 and was an associate clinical professor of medicine (infectious diseases) at Emory University.

During her medical residency at San Francisco General Hospital, Gerberding treated some of the first hospitalized AIDS patients.

She completed several studies on the risks of HIV to healthcare workers, created guidelines to prevent their infections, and established a treatment and research unit focused on HIV/AIDS cases among the urban poor.

In 1998, Gerberding was hired by the United States Centers for Disease Control and Prevention as the Director of the Division of Healthcare Quality Promotion.

There, she "developed CDC's patient safety initiatives and other programs to prevent infections, antimicrobial resistance and medical errors in healthcare settings."

Gerberding became a nationally-recognized figure during the 2001 anthrax attacks in the United States during her tenure as the acting deputy director of the National Center for Infectious Diseases, where she was a prominent spokeswoman for the CDC during daily briefings regarding the attacks and aftermath.

In September 2001, she became the acting deputy director of the National Center for Infectious Diseases (NCID).

During the 2001 anthrax attacks, Gerberding was part of a CDC team who regularly communicated with Congress, briefed the United States Health and Human Services senior staff, and communicated with the public about the crisis via daily press conferences.

Gerberding then served as CDC director from 2002-2009, and was then hired as an administrator at Merck.

In April 2002, after the resignation of CDC Director Jeffrey Koplan, Gerberding became the acting principal deputy director of the CDC and deputy director of the NCID.

In July 2002, Secretary of Health and Human Services Tommy Thompson named Gerberding as the director of the CDC and administrator for the Agency for Toxic Substances and Disease Registry (ATSDR).

In May 2004, the CDC announced a significant restructuring to improve its preparedness for several types of threats, to promote health, and to better prevent disease, injury and disability.

The reorganization was controversial, and Gerberding received bipartisan criticism from individuals and occupational health & safety groups, mainly centered around the implications of the restructuring for the National Institute for Occupational Safety and Health.

Other challenges of Gerberding's tenure as CDC Director included the American response to the global outbreak of Severe acute respiratory syndrome (SARS) and to several natural disasters, including Hurricane Katrina.

Gerberding resigned as CDC director effective on January 20, 2009, Barack Obama's inauguration day, to enable Obama's appointment for CDC director, Tom Frieden, to assume his position.

In December 2009, Gerberding became president of Merck's vaccine division.

In December 2014, the company announced her appointment as executive vice president for strategic communications, global public policy and population health.

In March 2022 it was announced that she would be retiring from Merck in May in order to assume the role as CEO of the Foundation for the National Institutes of Health (FNIH).

In April 2021, Gerberding told a Michigan news outlet that the United States' response to the COVID-19 pandemic was inadequate and that herd immunity to the virus would be challenging to achieve due to widespread vaccine hesitancy.

On May 30, 2021, Gerberding delivered the commencement address to the Washington University in St. Louis Class of 2020, whose commencement ceremonies were postponed until May 2021 due to the pandemic.